Browsing Tag
European Commission
245 posts
Pharma giants bag Lynparza EMA approval for metastatic breast cancer
Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency’s…
Regeneron and Sanofi’s Praluent gets European approval for reducing cardiovascular risk in atherosclerotic disease patients
Regeneron Pharmaceuticals and Sanofi have received a significant boost with the European Commission’s (EC) approval of Praluent (alirocumab)…
EC approves ADCETRIS for treating CD30+ Stage IV Hodgkin lymphoma
The European Commission (EC) has officially expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to include the…
Clovis Oncology secures EC approval for Rubraca’s new indication in ovarian cancer treatment
In a major win for Clovis Oncology, the European Commission (EC) has granted approval for an expanded indication…
Takeda’s $62bn acquisition of Shire: A game-changing move for global pharma
In a landmark deal, Takeda Pharmaceutical Company has successfully completed its previously announced acquisition of Shire, an Irish…
Novartis secures EC approval for Gilenya in pediatric multiple sclerosis treatment
Novartis has announced that the European Commission has expanded the approval of its multiple sclerosis drug, Gilenya (fingolimod),…
EC approves Pelmeg: Mundipharma’s answer to chemotherapy-induced neutropenia
Mundipharma, a German pharmaceutical company, has achieved a significant milestone with the European Commission (EC)’s approval of Pelmeg,…
Spark Therapeutics’ Luxturna gains EU approval as first gene therapy for inherited retinal disease
In a significant breakthrough for treating inherited vision loss, Pennsylvania-based Spark Therapeutics has received European Commission (EC) approval…
EC approves dosing flexibility for Novartis’s Cosentyx in psoriatic arthritis treatment
The European Commission (EC) has granted Novartis approval for a significant update to the label of its psoriatic…
Mylan launches Hulio, a biosimilar to Humira, across major European markets
Mylan has officially launched Hulio, its biosimilar to AbbVie’s Humira (adalimumab), across major European markets. This launch follows…